Chromomycin A3
WikiDoc Resources for Chromomycin A3 |
Articles |
---|
Most recent articles on Chromomycin A3 Most cited articles on Chromomycin A3 |
Media |
Powerpoint slides on Chromomycin A3 |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Chromomycin A3 at Clinical Trials.gov Trial results on Chromomycin A3 Clinical Trials on Chromomycin A3 at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Chromomycin A3 NICE Guidance on Chromomycin A3
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Chromomycin A3 Discussion groups on Chromomycin A3 Patient Handouts on Chromomycin A3 Directions to Hospitals Treating Chromomycin A3 Risk calculators and risk factors for Chromomycin A3
|
Healthcare Provider Resources |
Causes & Risk Factors for Chromomycin A3 |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Chromomycin A3 is a glycosidic antibiotic produced at the fermentation of a strain of Streptomyces griseus. It is also called toyomycin.
Uses
- Membrane-impermeant G/C-specific fluorescent DNA-binding dye.
- Antibacterial antibiotic.
- Antitumor antibiotic that inhibits RNA synthesis, especially in solid tumors
- Attention: actual medical use is unknown.